Distinct oligomeric assemblies of STING induced by non-nucleotide agonists

Anant Gharpure, Ariana Sulpizio, Johannes R. Loeffler, Monica L. Fernández-Quintero, Andy S. Tran, Luke L. Lairson () and Andrew B. Ward ()
Additional contact information
Anant Gharpure: Scripps Research
Ariana Sulpizio: Scripps Research
Johannes R. Loeffler: Scripps Research
Monica L. Fernández-Quintero: Scripps Research
Andy S. Tran: Scripps Research
Luke L. Lairson: Scripps Research
Andrew B. Ward: Scripps Research

Nature Communications, 2025, vol. 16, issue 1, 1-14

Abstract: Abstract STING plays essential roles coordinating innate immune responses to processes that range from pathogenic infection to genomic instability. Its adaptor function is activated by cyclic dinucleotide (CDN) secondary messengers originating from self (2’3’-cGAMP) or bacterial sources (3’3’-CDNs). Different classes of CDNs possess distinct binding modes, stabilizing STING’s ligand-binding domain (LBD) in either a closed or open conformation. The closed conformation, induced by the endogenous ligand 2’3’-cGAMP, has been extensively studied using cryo-EM. However, significant questions remain regarding the structural basis of STING activation by open conformation-inducing ligands. Using cryo-EM, we investigate potential differences in conformational changes and oligomeric assemblies of STING for closed and open conformation-inducing synthetic agonists. While we observe a characteristic 180° rotation for both classes, the open-LBD inducing agonist diABZI-3 uniquely induces a quaternary structure reminiscent but distinct from the reported autoinhibited state of apo-STING. Additionally, we observe slower rates of activation for this ligand class in functional assays, which collectively suggests the existence of a potential additional regulatory mechanism for open conformation-inducing ligands that involves head-to-head interactions and restriction of curved oligomer formation. These observations have potential implications in the selection of an optimal class of STING agonist in the context of a defined therapeutic application.

Date: 2025
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-025-58641-5 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-58641-5

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-025-58641-5

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().